Omnicell Net Income
| OMCL Stock | USD 36.50 0.57 1.54% |
As of the 10th of February, Omnicell holds the Risk Adjusted Performance of 0.042, coefficient of variation of 2321.97, and Semi Deviation of 3.4. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Omnicell, as well as the relationship between them. Please check Omnicell treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Omnicell is priced some-what accurately, providing market reflects its current price of 36.5 per share. Given that Omnicell has jensen alpha of 0.0171, we recommend you to check out Omnicell's recent market performance to make sure the company can sustain itself at a future point.
Omnicell Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.3998 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 2.1 M | 1.9 M | |
| Net Income Applicable To Common Shares | 6.5 M | 6.2 M | |
| Net Income From Continuing Ops | 11.3 M | 18.6 M | |
| Net Income Per Share | 0.04 | 0.05 | |
| Net Income Per E B T | 0.18 | 0.19 |
Omnicell | Net Income | Build AI portfolio with Omnicell Stock |
Historical Net Income data for Omnicell serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Omnicell represents a compelling investment opportunity.
Latest Omnicell's Net Income Growth Pattern
Below is the plot of the Net Income of Omnicell over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Omnicell financial statement analysis. It represents the amount of money remaining after all of Omnicell operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Omnicell's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Omnicell's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 2.05 M | 10 Years Trend |
|
Net Income |
| Timeline |
Omnicell Net Income Regression Statistics
| Arithmetic Mean | 19,008,553 | |
| Geometric Mean | 14,056,558 | |
| Coefficient Of Variation | 134.32 | |
| Mean Deviation | 19,165,127 | |
| Median | 16,161,000 | |
| Standard Deviation | 25,532,915 | |
| Sample Variance | 651.9T | |
| Range | 98.6M | |
| R-Value | 0.01 | |
| Mean Square Error | 695.3T | |
| R-Squared | 0.0002 | |
| Significance | 0.96 | |
| Slope | 63,040 | |
| Total Sum of Squares | 10430.9T |
Omnicell Net Income History
Other Fundumenentals of Omnicell
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Omnicell Net Income component correlations
Omnicell Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Omnicell is extremely important. It helps to project a fair market value of Omnicell Stock properly, considering its historical fundamentals such as Net Income. Since Omnicell's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Omnicell's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Omnicell's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. Anticipated expansion of Omnicell directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Omnicell assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.36) | Earnings Share 0.04 | Revenue Per Share | Quarterly Revenue Growth 0.023 | Return On Assets |
Understanding Omnicell requires distinguishing between market price and book value, where the latter reflects Omnicell's accounting equity. The concept of intrinsic value - what Omnicell's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Omnicell's price substantially above or below its fundamental value.
It's important to distinguish between Omnicell's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Omnicell should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Omnicell's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Omnicell 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Omnicell's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Omnicell.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Omnicell on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Omnicell or generate 0.0% return on investment in Omnicell over 90 days. Omnicell is related to or competes with Progyny, Schrodinger, Omada Health, Teladoc, 10X Genomics, Phreesia, and UFP Technologies. Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthc... More
Omnicell Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Omnicell's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Omnicell upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.65 | |||
| Information Ratio | 0.0124 | |||
| Maximum Drawdown | 23.86 | |||
| Value At Risk | (3.53) | |||
| Potential Upside | 5.25 |
Omnicell Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Omnicell's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Omnicell's standard deviation. In reality, there are many statistical measures that can use Omnicell historical prices to predict the future Omnicell's volatility.| Risk Adjusted Performance | 0.042 | |||
| Jensen Alpha | 0.0171 | |||
| Total Risk Alpha | (0.23) | |||
| Sortino Ratio | 0.0109 | |||
| Treynor Ratio | 0.102 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Omnicell's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Omnicell February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.042 | |||
| Market Risk Adjusted Performance | 0.112 | |||
| Mean Deviation | 1.99 | |||
| Semi Deviation | 3.4 | |||
| Downside Deviation | 3.65 | |||
| Coefficient Of Variation | 2321.97 | |||
| Standard Deviation | 3.21 | |||
| Variance | 10.29 | |||
| Information Ratio | 0.0124 | |||
| Jensen Alpha | 0.0171 | |||
| Total Risk Alpha | (0.23) | |||
| Sortino Ratio | 0.0109 | |||
| Treynor Ratio | 0.102 | |||
| Maximum Drawdown | 23.86 | |||
| Value At Risk | (3.53) | |||
| Potential Upside | 5.25 | |||
| Downside Variance | 13.3 | |||
| Semi Variance | 11.55 | |||
| Expected Short fall | (2.01) | |||
| Skewness | (1.70) | |||
| Kurtosis | 10.17 |
Omnicell Backtested Returns
As of now, Omnicell Stock is very steady. Omnicell maintains Sharpe Ratio (i.e., Efficiency) of 0.012, which implies the firm had a 0.012 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Omnicell, which you can use to evaluate the volatility of the company. Please check Omnicell's Semi Deviation of 3.4, risk adjusted performance of 0.042, and Coefficient Of Variation of 2321.97 to confirm if the risk estimate we provide is consistent with the expected return of 0.0397%. The company holds a Beta of 1.26, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Omnicell will likely underperform. Omnicell right now holds a risk of 3.31%. Please check Omnicell downside variance, and the relationship between the treynor ratio and kurtosis , to decide if Omnicell will be following its historical price patterns.
Auto-correlation | -0.36 |
Poor reverse predictability
Omnicell has poor reverse predictability. Overlapping area represents the amount of predictability between Omnicell time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Omnicell price movement. The serial correlation of -0.36 indicates that just about 36.0% of current Omnicell price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.36 | |
| Spearman Rank Test | -0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 15.64 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Omnicell Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Omnicell reported net income of 2.05 M. This is 99.4% lower than that of the Health Care Technology sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 99.64% higher than that of the company.
Omnicell Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Omnicell's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Omnicell could also be used in its relative valuation, which is a method of valuing Omnicell by comparing valuation metrics of similar companies.Omnicell is currently under evaluation in net income category among its peers.
Omnicell ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Omnicell's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Omnicell's managers, analysts, and investors.Environmental | Governance | Social |
Omnicell Institutional Holders
Institutional Holdings refers to the ownership stake in Omnicell that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Omnicell's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Omnicell's value.| Shares | Citadel Advisors Llc | 2025-06-30 | 898.2 K | Wellington Management Company Llp | 2025-06-30 | 804.2 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 711.1 K | Royal Bank Of Canada | 2025-06-30 | 695.1 K | Qube Research & Technologies | 2025-06-30 | 654 K | Charles Schwab Investment Management Inc | 2025-06-30 | 616 K | Federated Hermes Inc | 2025-06-30 | 594.9 K | Mirae Asset Global Etfs Holdings Ltd. | 2025-06-30 | 589.7 K | Northern Trust Corp | 2025-06-30 | 497.5 K | Blackrock Inc | 2025-06-30 | 7.8 M | Vanguard Group Inc | 2025-06-30 | 5.6 M |
Omnicell Fundamentals
| Return On Equity | 0.0017 | ||||
| Return On Asset | 0.003 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.01 % | ||||
| Current Valuation | 1.66 B | ||||
| Shares Outstanding | 44.88 M | ||||
| Shares Owned By Insiders | 1.82 % | ||||
| Shares Owned By Institutions | 98.18 % | ||||
| Number Of Shares Shorted | 2.68 M | ||||
| Price To Earning | 64.95 X | ||||
| Price To Book | 1.35 X | ||||
| Price To Sales | 1.44 X | ||||
| Revenue | 1.18 B | ||||
| Gross Profit | 508.04 M | ||||
| EBITDA | 90.12 M | ||||
| Net Income | 2.05 M | ||||
| Cash And Equivalents | 244.95 M | ||||
| Cash Per Share | 5.53 X | ||||
| Total Debt | 217.18 M | ||||
| Debt To Equity | 0.57 % | ||||
| Current Ratio | 2.11 X | ||||
| Book Value Per Share | 27.40 X | ||||
| Cash Flow From Operations | 127.3 M | ||||
| Short Ratio | 4.57 X | ||||
| Earnings Per Share | 0.04 X | ||||
| Price To Earnings To Growth | 2.28 X | ||||
| Target Price | 57.43 | ||||
| Number Of Employees | 3.6 K | ||||
| Beta | 0.77 | ||||
| Market Capitalization | 1.7 B | ||||
| Total Asset | 1.97 B | ||||
| Retained Earnings | 382.89 M | ||||
| Working Capital | 219.81 M | ||||
| Current Asset | 50.15 M | ||||
| Current Liabilities | 50.17 M | ||||
| Net Asset | 1.97 B |
About Omnicell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Omnicell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Omnicell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Omnicell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. Anticipated expansion of Omnicell directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Omnicell assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.36) | Earnings Share 0.04 | Revenue Per Share | Quarterly Revenue Growth 0.023 | Return On Assets |
Understanding Omnicell requires distinguishing between market price and book value, where the latter reflects Omnicell's accounting equity. The concept of intrinsic value - what Omnicell's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Omnicell's price substantially above or below its fundamental value.
It's important to distinguish between Omnicell's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Omnicell should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Omnicell's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.